An assessment of R&D productivity in the pharmaceutical industry.
Recent reports suggest that R&D productivity in the pharmaceutical industry can be strengthened by reducing costs both in the early phase and, mostly, in the clinical phase of drug discovery. However, a cost-benefit probabilistic analysis reveals that despite high costs, the clinical phase shows healthy productivity, whereas the early phase, particularly lead optimization, exhibits very low productivity.
Department of Economics, University of Siena, Siena, Italy. dimitri@unisi.it
Nicola
N
Dimitri
D000818:Animals; D035843:Biomedical Research / Q000191:economics; D055808:Drug Discovery / Q000191:economics; D004345:Drug Industry / Q000191:economics; D017598:Efficiency, Organizational / Q000191:economics; D006801:Humans; D015233:Models, Statistical; D012109:Research Support as Topic / Q000191:economics